Literature DB >> 22543428

Neurostimulation therapies for primary headache disorders: present and future.

Delphine Magis1, Rigmor Jensen, Jean Schoenen.   

Abstract

PURPOSE OF REVIEW: Most pharmacological treatments of primary headache disorders are partially effective and have cumbersome side effects. Therapies with better efficacy and tolerance are needed. Neurostimulation techniques may have this potential. This is an attempt to summarize the latest clinical trial results published in the field. RECENT
FINDINGS: Hypothalamic deep brain stimulation is effective in drug-resistant chronic cluster headache (drCCH) but not riskless. Recent anatomical MRI studies indicate that the effective stimulation sites are rather widespread. Occipital nerve stimulation (ONS) seems to be effective in up to 76% of drCCH patients and its benefit long-lasting. A minority of patients are able to abandon preventive drugs. Its mechanism of action appears nonspecific. In chronic migraine, randomized controlled trials of ONS showed recently encouraging results, but long-term studies are missing. An ongoing sham-controlled trial suggests sphenopalatine ganglion neurostimulation (SPGS) efficacy in drCCH acute treatment, but possibly also in preventive therapy. Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) modulate cortical excitability and connectivity. TMS could prevent headache when applied over the occipital cortex during the migraine aura. Repetitive TMS and tDCS have provided mixed results in a few small studies and warrant further trials.
SUMMARY: Neurostimulation therapies inaugurate a new era in headache management and offer a promising alternative to medications. Future studies are necessary to provide evidence-based efficacy data, knowledge on their mode of action and information about their pharmaco-economic advantages.

Entities:  

Mesh:

Year:  2012        PMID: 22543428     DOI: 10.1097/WCO.0b013e3283532023

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  16 in total

1.  Transcutaneous supraorbital neurostimulation for acute treatment of chronic migraine: open-label preliminary data.

Authors:  Paola Di Fiore; Alberto Galli; Giacomo D'Arrigo; Gennaro Bussone; Henri Didier; Domenico D'Amico; Fabio Frediani
Journal:  Neurol Sci       Date:  2018-06       Impact factor: 3.307

Review 2.  [Neurostimulation for treatment of headaches].

Authors:  H C Diener; K Rabe; M Gerwig; O Müller; U Sure; C Gaul
Journal:  Nervenarzt       Date:  2012-08       Impact factor: 1.214

3.  Repetitive Transcranial Magnetic Stimulation (rTMS)-Induced Trigeminal Autonomic Cephalalgia.

Authors:  Onur Durmaz; Mehmet Alpay Ateş; Mehmet Güney Şenol
Journal:  Noro Psikiyatr Ars       Date:  2015-07-07       Impact factor: 1.339

4.  Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial.

Authors:  Paola Di Fiore; Gennaro Bussone; Alberto Galli; Henri Didier; Cesare Peccarisi; Domenico D'Amico; Fabio Frediani
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

Review 5.  Management of fibromyalgia syndrome in 2016.

Authors:  Akiko Okifuji; Jeff Gao; Christina Bokat; Bradford D Hare
Journal:  Pain Manag       Date:  2016-06-16

6.  Role of neurostimulation in migraine.

Authors:  L Grazzi; A Padovan; P Barbanti
Journal:  Neurol Sci       Date:  2015-05       Impact factor: 3.307

7.  Refractory migraine: the role of the physician in assessment and treatment of a problematic disease.

Authors:  Bruno Colombo; Dacia Dalla Libera; Gloria Dalla Costa; Giancarlo Comi
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

Review 8.  Contributions of Nociresponsive Area 3a to Normal and Abnormal Somatosensory Perception.

Authors:  Barry L Whitsel; Charles J Vierck; Robert S Waters; Mark Tommerdahl; Oleg V Favorov
Journal:  J Pain       Date:  2018-09-15       Impact factor: 5.820

9.  Transcutaneous supraorbital neurostimulation in "de novo" patients with migraine without aura: the first Italian experience.

Authors:  Antonio Russo; Alessandro Tessitore; Francesca Conte; Laura Marcuccio; Alfonso Giordano; Gioacchino Tedeschi
Journal:  J Headache Pain       Date:  2015-07-22       Impact factor: 7.277

10.  High-dose intravenous methylprednisolone for the prophylactic treatment of cluster headache.

Authors:  Sanami Kawada; Kenichi Kashihara; Takaki Imamura; Manabu Ohno
Journal:  Springerplus       Date:  2013-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.